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Abstract
Background: There is a need to investigate biomarkers that are indicative of the progression of dementia in ethnic
patient populations. The disparity of information in these populations has been the focus of many clinical and
academic centers, including ours, to contribute to a higher success rate in clinical trials. In this study, we have
investigated plasma biomarkers in amnestic mild cognitively impaired (aMCI) female patient cohorts in the context
of ethnicity and cognitive status.
Method: A panel of 12 biomarkers involved in the progression of brain pathology, inflammation, and cardiovascular
disorders were investigated in female cohorts of African American, Hispanic, and White aMCI patients. Both
biochemical and algorithmic analyses were applied to correlate biomarker levels measured during the early stages
of the disease for each ethnicity.
Results: We report elevated plasma Aβ40, Aβ42, YKL-40, and cystatin C levels in the Hispanic cohort at early aMCI status.
In addition, elevated plasma Aβ40 levels were associated with the aMCI status in both White and African American
patient cohorts by the decision tree algorithm. Eotaxin-1 levels, as determined by the decision tree algorithm and
biochemically measured total tau levels, were associated with the aMCI status in the African American cohort.
Conclusions: Overall, our data displayed novel differences in the plasma biomarkers of the aMCI female cohorts where
the plasma levels of several biomarkers distinguished between each ethnicity at an early aMCI stage. Identification of
these plasma biomarkers encourages new areas of investigation among aMCI ethnic populations, including larger
patient cohorts and longitudinal study designs.
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Background
The use of biomarker data to detect early Alzheimer’s
disease (AD) has significant benefits in therapeutic and
diagnostic implications [1]. The new criteria and guide-
lines for diagnosis of AD and its early clinical stage of
“Mild Cognitive Impairment due to AD” (MCI-AD) [2]
and “Prodromal or amnestic AD” (aMCI) [3] highlights
the importance of identifying early detection of specific
and sensitive biomarkers as an effective disease
intervention strategy [4, 5]. Cerebrospinal fluid (CSF)
has been used to identify specific biomarkers that aid in
the early detection of AD [6]. However, due to the
invasive nature of CSF collection, the utilization of
biological samples, such as plasma, presents a more
feasible option [1, 7]. Studies have shown that high Aβ42
levels in plasma were linked to the low incidence of AD,
while significant reduction of total tau levels in plasma
was detected in AD patients, suggesting the viability of
both proteins as biomarkers in AD [8, 9].
The study of supplemental cardiovascular and inflam-
matory biomarkers may also allow for an effective early
diagnosis. This is especially relevant in ethnic populations,
such as African American and Hispanic communities,
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where the prevalence for vascular diseases associated with
high blood pressure and diabetes are higher with no
known genetic factors explaining the increased incidence
[10, 11]. Despite the association of cardiovascular risk
factors with the increased risk of AD in African Americans,
few studies have focused on the neuropathological associ-
ation in this population [12–14]. Laboratory research and
genome-wide association studies (GWAS) have recognized
the impact of inflammation on AD pathology [15–17].
Indeed, a multitude of studies have investigated inflamma-
tory markers as potential biomarkers in AD progression
[18–20]; however, the data obtained from studies measuring
levels of cytokines, cytokine receptors, and other proteins
associated with immune responses in blood and CSF of AD
patients are inconsistent. As our understanding on the
impact of sex or ethnicity in disease progression increases,
so should our efforts to design longitudinal and cross-
sectional studies that extricate the progression of AD in
well-controlled patient cohorts based on these parameters.
In this study, we aimed to identify biomarkers that link
the incidence of aMCI/prodromal AD disease status to
specific vascular, inflammatory, and other plasma bio-
markers in ethnic female patient populations. We evalu-
ated plasma samples of 75 female subjects from African
American, Hispanic, and White ethnic backgrounds who
were participants in the Florida Alzheimer’s Disease
Research Center Clinical Core (FADRC-CC) in Miami
Beach and Tampa, Florida [21]. All patients were
classified as amnestic MCI (aMCI)/prodromal AD based
on an approved consensus diagnosis as described previ-
ously [21, 22]. Further, we utilized computational ana-
lysis (i.e., a decision tree model) and correlational
models to predict early AD plasma biomarkers present
in each of the ethnic groups. We report elevated plasma
levels of Aβ40, Aβ42, YKL-40, and cystatin C in the
Hispanic AD cohorts by both biochemical and computa-
tional analyses. Increases in plasma Aβ40 levels were also
demonstrated in aMCI patients in the White cohort, and
a significant reduction in total tau levels were detected
in the aMCI African American patient cohort. Further,
with the algorithmic decision tree model we identified
Aβ40 and eotaxin-1 as potential early indicators of AD
progression in the African American female cohort. All
together, these findings provide the necessary data for
designing longitudinal studies where large ethnic groups
can be included, and the biomarker selection can differ-
entiate among ethnic groups and disease status.
Methods
Subjects and aMCI diagnosis
Plasma samples were obtained from the University of
South Florida (USF) FADRC-CC database belonging to
African American, Hispanic, and White female patients
who were treated and evaluated at the Byrd Alzheimer’s
Institute between the years 2006 and 2011. The FADRC-
CC subjects had previously undergone neuropsychological
tests as outlined in the National Alzheimer’s Coordinating
Center (NACC) Uniform Data Set (UDS). Consesus
diagnosis of the subjects was based on the physician's
cognitive diagnosis, neuropsychological diagnosis, traditional
consensus diagnosis, algorithmic diagnosis, and digital
MRI scans [21]. Further, based on the FADRC-CC archival
data, the Mini-Mental State Examination (MMSE), the
Global Clinical Dementia Rating Scale (CDR), and neuro-
physiological assessment were also used for diagnosis [21].
For the classification of aMCI/prodromal AD, previously
approved consensus was followed [21–23]. In addition, the
International Statistical Classification of Diseases, 10th
Revision and the Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition criteria were met [24].
Of the 75 female ethnic subjects, 30 samples belonged
to age-matched female controls (n = 10/group) and 45
samples belonged to female patients diagnosed with
aMCI/prodromal AD disease stage (n = 15/group) based
on the aforementioned diagnostic criteria [21, 22]. The
White, African American, and Hispanic patient cohorts
averaged an age of 76.23 ± 1.47 years (age range: 60–85
years) and maintained an averaged MMSE score of
26.88 ± 1.06 and CDR of 1.00 ± 0.5. The age-matched
control population had an average age of 72.97 ± 1.60
and maintained an average MMSE value of 28.82 ± 0.45
and a CDR value of 0. The specific demographics of each
ethnic cohort are presented in Table 1. Further, the level
of education of each patient included in the study, which
can be associated with patient cognitive reserve [25],
and the patients’ApoE genotype [26, 27] did not account
Table 1 Demographics of female patients among the ethnic groups
NC aMCI MMSE CDR
Age (years) (± SEM) n Age (years) (± SEM) n NC aMCI NC aMCI
White 73.40 ± 1.40 10 73.47 ± 1.17 15 28.71 ± 0.46 26.83 ± 1.58 0.00 ± 0.00 1.00 ± 0.39
African American 70.00 ± 1.86 10 76.73 ± 1.82 15 29.25 ± 0.31 27.15 ± 0.68 0.00 ± 0.00 1.00 ± 0.58
Hispanic 75.5 ± 2.04 10 78.50 ± 1.69 15 28.50 ± 0.56 26.67 ± 0.91 0.00 ± 0.00 1.00 ± 0.50
Plasma samples from African American, Hispanic, and White female patients diagnosed with aMCI (n = 15/ethnicity) and age-matched individuals (n = 10/ethnicity).
Patients’ age (year), MMSE scores, and CDR values for each ethnic group are indicated as average (± SEM)
aMCI amnestic mild cognitive impairment, MMSE Mini-Mental State Examination CDR Global Clinical Dementia Rating Scale, NC age-matched control group
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for the cognitive status and other outcomes measured
here. In addition, patients with disclosed cardiovascular
and inflammatory conditions were used as exclusion cri-
teria for this study. Plasma from all control and aMCI
subjects was prepared according to the Clinical Labora-
tory Improvement Amendments (CLIA) standards,
which deemed these samples suitable for clinical trial
work.
Multiplex assay
The plasma samples were prepared with ethylenedi-
aminetetraacetic acid (EDTA) based on the CLIA
standards. Milliplex Multiplex assays, commercially
available customized plates, were used with few modifi-
cations to the manufacturer’s instructions. The following
plasma biomarkers were purchased from EMD Milli-
pore: total tau (catalogue number HND1MAG-39 K),
phosphorylated tau (catalogue number HND1MAG-39
K), C-reactive protein (catalogue number HCVD3MAG-
67 K), fibrinogen (catalogue number HCVD3MAG-67
K), plasminogen activator/inhibitor (catalogue number
HADK1MAG-61 K), MCP-1 (catalogue number
HCYTOMAG-60 K), eotaxin-1 (catalogue number
HCYTOMAG-60 K), and YKL-40 (catalogue number
HCMBMAG-22 K). The standards, controls, and subject
samples were incubated with fluorescent-coded magnetic
MagPlex-C microspheres overnight at 4 °C, and add-
itionally incubated with a biotinylated detection antibody
for 1 hour at room temperature (RT). The streptavidin–
phycoerythrin conjugate was added and incubated at RT
for 30 minutes, and then rinsed three times. The plates
were read using Luminex xMAP technology (Bio-Rad
Laboratories, Inc., Hercules, CA, USA) where micro-
spheres were counted based on fluorescent reporter
signals.
ELISA assay
R&D Systems Quantikine ELISA kits (R&D Systems,
Inc., Minneapolis, MN, USA) measured progranulin
(catalogue number DPGRN0) and cystatin C (catalogue
number DSCTC0). The assay diluent was added to each
well, precoated with antibody, prior to addition of stand-
ard, control, and subject samples, incubated for 2 hours
at RT, and washed four times with wash buffer. An
enzyme-linked human progranulin or human cystatin C
conjugate was introduced into the wells. The plates were
rinsed and incubated for 30 minutes at RT with sub-
strate solution followed by the addition of a stop solu-
tion. The ELISA plates were read with the BioTek plate
reader at wavelengths 540 nm and 570 nm and analyzed
via the Gen5 program.
For determination of human plasma Aβ40 and Aβ42
levels, we used ELISA kits according to the manufac-
turer’s protocol (KHB3482 for Aβ40, KHB3442 for Aβ42;
Invitrogen, Waltham, CA, USA). Optical density and
concentrations were calculated according to the stand-
ard curve.
Decision tree analysis
The decision tree model was developed as described re-
cently [28]. The biomarker data gathered for each ethnic
group are used to identify homogeneous subgroups em-
bedded in each ethnicity whose members have similar
biomarker levels. Model 1 (M1) describes a decision tree
on data from African American female patients; Model 2
(M2) describes a decision tree on data from Hispanic
female patients; and Model 3 (M3) describes a decision
tree on data from White female patients. The decision
trees are generated using conditional recursive partition-
ing, which recursively seeks cutoff values of the best
biomarkers that can segment the population into homo-
geneous subgroups while the homogeneity of the sub-
groups is measured by the variation of the outcome
variable. The final product of this method is a set of sub-
groups where each subgroup is defined as a rule that
consists of multiple biomarkers and their cutoff values. In
this method, we try to find rules that identify homoge-
neous subgroups of aMCI subjects or age-matched con-
trol individuals from the initial population. Specifically, as
a recursive procedure, the algorithm grows the decision
tree from the “root node” that includes all of the subjects.
The algorithm then considers all of the possible cutoff
values for each biomarker and uses univariate tests to find
the best biomarker and its cutoff value to split the subjects
in the root node into two partitions, resulting in two
nodes. This split procedure is then repeated on each of
the two nodes, further purifying the subgroups by splitting
each node into two new nodes. This process is repeated
until each node includes the predetermined number of in-
dividuals. When this process is terminated, the final sub-
groups or nodes would be the terminal nodes of the tree.
We used the “party” package from R version 3.2.0 (http://
www.r-project.org/) to develop the decision trees as a tool
for classifying aMCI subjects and age-matched controls.
Statistical analysis
All raw values of analytes measured with Milliplex
Multiplex assays were adjusted using Milliplex Analyst
5.1 (Millipore, Billerica, MA, USA). In order to achieve
normal distribution, the raw values of the analytes were
adjusted by a standard curve (five-parameter logistic re-
gression or five-parameter linear regression) that best fit
the data. All raw values of analytes measured with R&D
Systems Quantikine ELISA kits were adjusted using Elisa
Analysis (2012). Normal distribution was achieved when
the raw values were adjusted by the standard curve
(five-parameter logistic regression) that best fit the data.
Human plasma Aβ40 and Aβ42 levels using ELISA kits
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were adjusted using a best-fit standard curve created in
Microsoft Excel (2010).
Statistical analysis in this study was performed in IBM
SPSS 22.0 (IBM, Chicago, IL, USA). Using SPSS 22.0, a
two by three factorial design with post-hoc analyses was
used to compare age-matched controls and aMCI pa-
tients for each ethnicity. The pairwise comparison yield
was used to determine significant changes between the
normal controls and aMCI patients for each ethnic
group (p ≤ 0.05). In IBM SPSS 22.0, an outlier test was
performed, and data points that did not pass the test
were excluded from further statistical analyses. Student’s
t-test analysis was used to compare age-matched con-
trols with aMCI patients (p ≤ 0.05). Graphs were gener-
ated using GraphPad Prism 5.0 (GraphPad Software, La
Jolla, CA, USA).
Results
Ethnic patient and control population demographics and
cognitive functioning criteria
There is a pressing need to find blood-based biomarkers
that, with high sensitivity and specificity, can determine
early AD risk and develop preventive therapies [29]. In
our study, the aMCI patient population (n = 15/group)
and age-matched controls (n = 10/group) consisted of
White, African American, and Hispanic patients. The
specific population demographics of each cohort and
ethnicity are presented in Table 1.
Evidence suggests that levels of plasma Aβ40, Aβ42,
total tau, phosphorylated tau, and cystatin C, in associ-
ation with the development of neuropathology in AD
brain, are well-established and internationally validated
plasma biomarkers in AD [30–33]. Because their tem-
poral detection levels are debated, we have included
these potential biomarkers in this study [34–36]. In
addition, vascular and inflammatory biomarkers are also
potential factors that could provide a significant role in
the early detection of AD [12, 37]. A list of all bio-
markers measured in our cohort is presented in Table 2.
Elevated plasma amyloid, tau, YKL-40, and cystatin C
levels among female patients
The analysis of biomarkers was conducted using plasma
collected during patient visits. First, we measured levels
of Aβ40, Aβ42, and their ratio (Aβ42/Aβ40) in the plasma
of each ethnic group and their respective normal age-
matched controls (Fig. 1 and Additional file 1: Figure
S1). The plasma Aβ40 levels displayed significant in-
creases in the aMCI patient populations compared with
the age-matched control group, independent of ethnicity
(Fig. 1 and Table 3, p = 0.0001, Student’s t test). When
controlled for ethnicity and disease status, our data
analyses (IBM SPSS Statistics Desktop, V22.0) revealed
pairwise significance (Fig. 1). Plasma Aβ40 levels were
significantly increased in the aMCI female White patients
(Fig. 1a and Table 4, p = 0.0001, 96.0 vs 160.5 pg/ml,
95 % CI: 58.0–134.0) and Hispanic patients (Fig. 1a
and Table 4, p < 0.05, 104.8 vs 127.6 pg/ml, 95 % CI:
66.8–142.8) compared with their respective control
groups. Further, increased plasma Aβ42 levels were
significantly associated with the incidence of aMCI in
the Hispanic patient population compared with its
control (Fig. 1b and Table 4, p < 0.005, 23.7 pg/ml vs
40.4 pg/ml, 95 % CI: 15.5–31.8); however, this did not
occur in either the White or African American pa-
tient cohorts. Plasma total tau levels were significantly
decreased in the African American patient cohort
(Fig. 1e and Table 4, p < 0.05, 0.11 vs 0.04 ng/ml, 95 % CI:
0.055–0.151) while its levels were unchanged in the
Hispanic and White female patient cohorts. The levels of
phosphorylated tau in plasma from all three patient co-
horts remained unchanged at this early stage of dementia
(Fig. 1f, Table 4, and Additional file 2: Table S1, SPSS
statistical analysis).
Studies have associated cystatin C levels with the path-
ology of AD [31]. Our data demonstrated significant in-
creases in cystatin C levels in the plasma of aMCI patients
from all three patient cohorts compared with age-
matched controls (Fig. 1g and Table 3, Student’s t test,
p < 0.005). When corrected for ethnicity and disease
status, plasma levels of cystatin C were significantly
higher in Hispanic aMCI female patients compared
with the Hispanic age-matched control group (Fig. 1g,
p < 0.05, 1042.7 vs 1303.4 ng/ml, 95 % CI: 844.8–1240.7).
All collected data are summarized in Additional file 2:
Table S1.
Plasma inflammation and vascular biomarker associations
in female patients
Inflammatory biomarkers are of interest due to the asso-
ciation of proinflammatory cytokines in the cascade
leading to the progression of plaques and neurofibrillary
tangle pathology in AD [38]. Utilizing the multiplex
technology, we found a significant increase in YKL-40
levels in the plasma of the Hispanic aMCI patient cohort
compared with its respective age-matched control (Fig. 1d,
p < 0.05, 54.2 vs 114.1 ng/ml, 95 % CI: 10.7–97.7). Interest-
ingly, studies have shown increased levels of YKL-40 in
very mild and mild AD-type dementia compared with
control subjects [39], suggesting the validity of YKL-40 as
an early biomarker in general patient AD populations and
specifically in those of Hispanic ethnicity.
The progression of AD and vascular diseases are
highly increased with age [40]. Studies suggest that
cerebrovascular disease and high cholesterol levels may
be associated with AD [13, 14], and they relate to vascu-
lar conditions that are otherwise prominent risk factors
for AD in African Americans [41, 42]. Therefore, plasma
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levels for vascular risk factors such as fibrinogen, plas-
minogen activator/inhibitor (PAI.1), and C-reactive pro-
tein (CRP) were measured in aMCI and aged-matched
patient cohorts (Additional file 1: Figure S1). Statistical
analysis revealed no significant difference in the plasma
levels of vascular biomarkers between the control and
patient cohorts controlled for ethnicity and cognitive
status (Additional file 1: Figure S1 and Additional file
2: Table S1).
Decision tree analysis identifies significant correlation
between various markers and amyloid levels in the
plasma of female patients
Next, we applied the decision tree (described in
Methods), a computational modeling algorithm, to our
data set in order to identify homogeneous subgroups
with similar biomarker levels that link them to the risk
of developing AD in each ethnic group (Fig. 2). The de-
cision tree model applied for the African American fe-
male cohort (M1) identified three biomarkers—Aβ40,
plasminogen activator/inhibitor (PAI.1), and eotaxin-
1—which can characterize two homogeneous subgroups
as Node 3 and Node 7. Node 3 is based on M1_Rule1
(Aβ40 ≤ 126.37 pg/ml and PAI.1 > 19229 pg/ml), which
associates high levels of PAI.1 with increased age. Node
7 identifies a homogeneous subject group (n = 7), which
can be characterized following M1_Rule2: Aβ40 > 126.27
pg/ml and eotaxin-1 > 103.14 pg/ml (Fig. 2a). Interest-
ingly, Aβ40 and eotaxin-1 were most strongly associated
with aMCI in the African American patients with
plasma levels above 126.27 pg/ml and 103.14 pg/ml,
respectively (Fig. 2a).
M2 model of the white female cohort identi-
fied three biomarkers; cystatin C, fibrinogen, and
PAI.1, which were linked linked to 3 subgroups fol-
lowing the rule: M2_Rule1 identifies Node 3 as a
homogeneous age-matched control group character-
ized as cystatin C ≤ 1312.95 ng/ml and fibrinogen >
2352.15 μg/ml; M2_Rule2 identifies Node 6 as a
heterogeneous population of the aMCI patient group (n =
7/8 aMCI) characterized as cystatin C ≤ 1312.95 ng/ml,
fibrinogen ≤ 2352.15 μg/ml, and PAI.1 ≤ 22105 pg/ml; and
M2_Rule3 identifies Node 7 as a homogeneous aMCI sub-
ject group characterized as cystatin C > 1312.95 ng/ml
(Fig. 2b).
M3 was built on the Hispanic cohort dataset and
identified Aβ40 and cystatin C as biomarkers linked
to one homogeneous subgroup of aMCI subjects
(Fig. 2c). Node 5 is characterized by M3_Rule1:
Aβ40 > 88.5 pg/ml and cystatin C > 1076.79 ng/ml.
Interestingly, when the cystatin C rule in this deci-
sion tree was applied to the other two ethnicities,
the majority of White and African American individ-
uals who satisfy this rule were also classified as aMCI
(data not shown). This suggests that cystatin C is as-
sociated with aMCI and should be studied further as
a potential early detector of AD.
For each model, the sensitivity measured the ability of
the model to identify the aMCI subjects, and the specifi-
city determined the ability of the model to identify actual
age-matched controls. Both sensitivity and specificity of
M1 (93 % and 70 %, respectively) and M2 (87 % and 90
%, respectively) are satisfactory. M3 has a sensitivity of
only 66.7 % and was unable to detect a homogeneous
aMCI subgroup, although this model was performed
Table 2 Plasma biomarkers measured for each category reflecting neuropathological, vascular, and inflammatory implications
Biomarker Type Regulation in AD References
Aβ40 Neuropathological ↑ Mehta et al., 2000 [45]
Aβ42 Neuropathological ↓ Craig-Schapiro et al., 2009 [56]
Total tau Neuropathological ↑ Sunderland et al., 2003 [64]
Phospho-tau Neuropathological ↑ Hampel and Teipel, 2004 [65]
Cystatin C Neuropathological ↓ Sundelof et al., 2008 [55]
Hu et al., 2012 [66]
C-reactive protein (CRP) Vascular ↑ Yasojima et al., 2000 [67]
Hu et al., 2012 [66]
Cortes-Canteli et al., 2012 [68]
Fibrinogen Vascular ↑ Hu et al., 2012 [66]
Plasminogen activator/inhibitor Vascular ↑ Oh et al., 2014 [60]
MCP-10 Inflammatory ↑ Galimberti et al., 2006 [69]
Eotaxin 1G Inflammatory ↑ Choi et al., 2008 [37]
YKL-40G Inflammatory ↑ Craig-Schapiro et al., 2010 [39]
Progranulin G Inflammatory ↑ D’Alton and Lewis, 2014 [70]
Biomarkers were chosen based on preclinical and clinical relevance to AD. Arrows indicate changes in biomarkers suggested from referred literature
AD Alzheimer’s disease
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with 100 % specificity. Overall, all three models dis-
played strong associations with aMCI despite the low
sample size (n = 75) [43].
Discussion
In this study, we analyzed a series of pathological,
vascular, and inflammatory biomarkers in the plasma of
African American, White, and Hispanic female aMCI
patients and age-matched control individuals. The goal
of this study was to determine effective potential bio-
markers that are specific for each ethnicity and can be
used for early detection of AD. Based on the multiplex
biochemical findings, we applied a set of algorithmic
rules which enabled us to identify biomarkers that are
associated with AD progression. Because of the signifi-
cant role of extracellular Aβ levels in the progression of
AD [44], we investigated its plasma levels as a potential
biomarker of aMCI disease stage in the study. An overall
significant increase of Aβ40 plasma concentrations com-
pared with the normal controls was shown. Plasma Aβ40
was also significantly increased in the White (p = 0.0001)
and Hispanic (p < 0.05) aMCI patient cohorts, while
plasma Aβ42 levels were significantly increased in the
Hispanic aMCI patient cohort compared with its age-
matched control (p < 0.005). Furthermore, the decision
tree model identified that Aβ40 plasma levels were



















































































2 African American Control
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4 Caucasian aMCI
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Aβ42/40
Fig. 1 Plasma biomarkers revealing significant association with the incidence of aMCI in ethnic cohorts. a Aβ40 levels were significantly increased
in White (p = 0.0001, 95 % CI: 58.0–134.0) and Hispanic (p < 0.01, 95 % CI: 66.8–142.8) aMCI patients compared with their respective age-matched
control group (NC). b Plasma Aβ42 levels were significantly increased in the Hispanic aMCI patient population (p < 0.005, 95 % CI: 15.5–31.8)
compared with the NC group. c Aβ42/Aβ40 ratio displayed no significant changes among aMCI ethnic groups. d YKL-40 levels were significantly
increased in the aMCI group of the Hispanic population compared with its NC group (p < 0.05, 95 % CI: 10.7–97.7). e Plasma total tau levels were
significantly associated with aMCI incidence in the African American aMCI patient cohort (p < 0.05, 95 % CI: 0.06–0.15), while f plasma phospho-tau
levels remained unchanged independent of ethnicity and disease progression. g Plasma cystatin C levels in the Hispanic patient cohorts are associated
with the incidence of aMCI (p < 0.05, 95 % CI: 844.8–1240.7). Statistical analyses were performed in a two by three factorial design with
post-hoc analyses using IBM SPSS Statistics 22. An outlier test via IBM SPSS Statistics 22 was performed on each data set and outliers
were removed. aMCI amnestic mild cognitive impairment
Table 3 Statistical analysis of association between normal
control and aMCI cohorts, independent of ethnicity
Biomarker p value, NC vs aMCI
Aβ40 0.0001***
Cystatin C 0.0024***
Indicated plasma levels of Aβ40 and cystatin C levels were significantly
increased in aMCI patients compared with the age-matched NCs, independent
of ethnicity (***p = 0.0001 and ***p = 0.0024, respectively). Other biomarkers
displayed no significant changes in the plasma levels between the NC group
and aMCI female patients (data not shown, p > 0.05). Statistical analyses were
performed using Student’s t test
aMCI amnestic mild cognitive impairment, NC age-matched control group
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associated with the aMCI status of the African American
female cohort. Studies have demonstrated conflicting
results regarding amyloid levels in plasma, where both
increases [45] or no significant changes [8] in Aβ40 levels
between AD patients and normal controls have been
reported. The discrepancies in the amyloid levels
measured in these studies could reflect several issues
that many laboratories face with sample treatment and
analytical assays utilized for measurement of Aβ in
plasma. A detailed discussion on preanalytical methods
and protocols to ensure consistency among studies has
been outlined in the new guidelines [46]. Further, contri-
bution of several differential genetic factors, differences
in prevalence of nongenetic medical risk factors, social
reaction to cognitive decline, and environmental risk fac-
tors represent ultimately the statistical limitation of
many reported studies.
Accumulation of hyperphosphorylated tau into neuro-
fibrillary tangles in the brain is highly correlated with
clinical manifestations and memory loss of AD patients
[47]. This study found a significant decrease in the levels
of total tau in the African American female aMCI stage
patients compared with the age-control group, with no
changes in phosphorylated tau levels among all ethnici-
ties. Zetterberg et al. [30] found that plasma total tau
levels were significantly elevated in AD patients, but not
in MCI patients, when compared with normal controls.
The authors suggested that plasma total tau levels may
be elevated to abnormal levels in the later disease stages,
and therefore plasma tau would be considered a late bio-
marker [30]. The lack of significant changes reported in
the aforementioned studies could be due to overall low
concentrations of total tau in plasma as well as the limi-
tations that each analytical assay represents [48]. The
disparity of data associated within each specific ethnicity
and/or sex could also contribute to the discrepancies be-
tween published reports.
Cystatin C is highly relevant to the progression of AD
[49]. While a case–control genetic association study has
linked the polymorphism of the cystatin C gene with the
risk for late-onset AD [50], others have demonstrated
that cystatin C polymorphism is a risk factor in early-
onset AD [51]. In fact, early research links cystatin C
with Aβ found in the vascular walls and senile plaque
cores in the brains of patients with AD [52]. An amount
of evidence suggests that cystatin C could even protect
the brain against amyloid-induced toxicity by binding to
Aβ protein and inhibiting Aβ42 oligomer and fibril forma-
tion [52–54]. A study examining an AD patient cohort
consisting of older men aged 77 years found that the
reduction of serum cystatin C levels was significantly
associated with the increased risk of AD [55]. In our study,
cystatin C levels were significantly increased in the aMCI
female population compared with the age-matched con-
trols. Further, we report that cystatin C was significantly
higher in Hispanic aMCI female patients compared with
the Hispanic age-matched control group (p < 0.05). The
computational analysis on the Hispanic cohort dataset
identified cystatin C as a biomarker linked to a homoge-
neous aMCI subgroup, suggesting that cystatin C can play
an important role in the early detection of AD. Interest-
ingly, when this algorithm (cystatin C > 1076.79 ng/ml)
was applied to the White and African American cohorts,
the majority of subjects that satisfied the rule were aMCI
patients. Altogether, our finding adds to the growing body
of literature suggesting that cystatin C may modulate the
clinical progression and cognitive decline in the disease
and can be suggested as a therapeutic biomarker for the
early detection of AD (Fig. 3) [31].
We demonstrated that plasma levels of YKL-40 were
elevated in the Hispanic aMCI female patients compared
with the respective age-matched controls (p < 0.05).
Interestingly, inflammatory markers including MCP-1
and progranulin were not significantly modified in the
female patient cohort (independent of ethnicity), despite
the potential of these markers as early detectors in the
diagnosis of AD. The significant increase in YKL-40, a
Table 4 Statistical analysis of association between normal
control and aMCI ethnic cohorts










Total tau White 0.3700
African American 0.0460*
Hispanic 0.7070






Indicated are the levels of biochemically measured plasma biomarkers that
displayed significant changes controlled for ethnicity and compared with NC
cohort. Statistical analyses were performed in a two by three factorial design
with post-hoc analyses using IBM SPSS Statistics 22. An outlier test was also
performed using IBM SPSS Statistics 22. Significant changes in biomarkers
related to ethnic background: *p < 0.05, **p < 0.01 ***p < 0.001
aMCI amnestic mild cognitive impairment, NC age-matched control group
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marker for neuroinflammation, in the Hispanic aMCI
cohort is of great interest because YKL-40 elevation in
both the CSF and plasma of MCI and mild AD-type de-
mentia patients has been reported [56, 57]. However, a re-
cent study suggested that increased YKL-40 levels in CSF
does not provide higher diagnostic accuracy compared
with CSF Aβ and tau levels [58], but notably reflecting the
ongoing synaptic degeneration and glial activation in AD.
Our findings corroborate the claim that YKL-40 can be a
viable biomarker for early detection of AD, especially
when controlled for ethnicity and sex.
Furthermore, the decision tree model identified Aβ40
and eotaxin-1 levels that were associated with aMCI in
the African American female cohort. Interestingly, a
human whole-genome study identified that a haplotype
of SNPs on chromosome 17, a chemokine gene cluster
(which includes eotaxin-1), was associated with age of
onset in familial AD [59]. Another study measuring
chemokine and cytokine levels in a cohort consisting of 13
controls and 11 AD patients reported significant elevation
of serum eotaxin-1 levels in aMCI patients compared with
the control group; however, the study did not account for
differences between ethnic groups in their patient cohort
[37]. Hereby, our findings suggest that increased eotaxin-1
plasma levels in the African American female population
could reflect early changes in this cohort, a relationship
that has yet to be studied.
Despite the nonsignificant changes measured in the
cardiovascular biomarkers levels in our patient cohort,
computational analysis identified that the combination
Fig. 2 Decision tree models for each ethnic group represent biomarkers linked to the risk of developing AD. Each node represents the subgroups
of patients obeying the rule of similar biomarker levels linked to the probability of developing aMCI for the given sample size. The sensitivity and
specificity for each decision tree was determine
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of cystatin C ≤ 1312.95 ng/ml, fibrinogen ≤ 2352.15 μg/ml,
and PAI.1 ≤ 22105 pg/ml is associated with 87 % of White
female aMCI patients. One limitation in applying these
analyses is the low sample size of patients enrolled in this
study; therefore, the models applied here are only suggest-
ive of relevant biomarkers. Cardiovascular markers have
been shown to be modified during AD progression
[13, 14]; for example, Oh et al. [60] reported in-
creased levels of plasma PAI-1 levels in MCI and AD
subjects as compared with normal controls. The authors
also reported that the PAI-1 levels were gradually in-
creased as the dementia progressed [60]. The discrep-
ancy in our findings and those reported may be due
to various methodological and analytic differences, in-
cluding the patients’ ethnic background, sex, and
medication history and the temporal expression pro-
file of vascular factors. These factors and others can,
for example, interfere with the biomarker plasma con-
centration [14].
Because GWAS confirmed the APOE e4 allele as a risk
factor and identified ABC7, a membrane transporter
protein, to be a strong genetic risk factor of AD in
African Americans [61], both genes represent important
correlative risk factors for future studies in the context
of ethnicity and cognitive performance. We believe that
finding biomarkers which link biological risk factors to
cognitive function and determining biomarker disparity
among ethnic groups can significantly advance research
for the development of effective preventive therapeutic
interventions in the treatment of AD.
Conclusion
We report that elevated plasma Aβ40, Aβ42, cystatin C,
and YKL-40 levels were associated with aMCI incidence
in the Hispanic cohorts by both biochemical and com-
putational analyses. Statistical analyses also showed that
plasma Aβ40 and total tau levels were associated with
the incidence of aMCI in the White cohort and African
American cohort, respectively. By applying algorithmic
rules in a decision tree model, we identified Aβ40 and
eotaxin as potential early indicators of AD in the African
American aMCI patient cohort, based on their sex and
ethnicity. To our knowledge, very few studies have
analyzed the relation of ethnicity to AD in such an in-
clusive panel of biomarkers. Considering that clinical
manifestations are often the result of complex extrinsic
social factors, there is growing awareness that these fac-
tors may influence some of the disparities in clinical
presentation and treatment [62, 63].
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